SCHEMBL29601219

SCHEMBL29601219

Cn1nc(C(=O)O)c2[nH]c3cccnc3c21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 3/20 0.51
ADORA2A P29274 3/20 0.51
ADORA1 P30542 2/20 0.51
KLK6 Q92876 2/20 0.40
MYC P01106 1/20 0.38
KDM4E B2RXH2 2/20 0.37
L3MBTL1 Q9Y468 2/20 0.37
ALDH1A1 P00352 1/20 0.37
CYP3A4 P08684 1/20 0.37
MAPT P10636 1/20 0.37
ALOX15 P16050 1/20 0.37
TSHR P16473 1/20 0.37
BLM P54132 1/20 0.37
AGER Q15109 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
DYRK1A Q13627 2/20 0.36
CDK9 P50750 1/20 0.36
DYRK1B Q9Y463 1/20 0.36
PARP1 P09874 1/20 0.36
TET2 Q6N021 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29615773 0.88 ADORA3 (0.50) ADORA3ADORA2AADORA1KLK6KDM4E
SCHEMBL31458675 0.86 ADORA3 (0.48) ADORA3ADORA2AADORA1KLK6KDM4E
SCHEMBL23495801 0.71 KDM4E (0.41) ADORA3ADORA2AADORA1KDM4EL3MBTL1
SCHEMBL12266002 0.71 KDM4E (0.41) MYCKDM4EL3MBTL1ALDH1A1CYP3A4
SCHEMBL29600787 0.71 KDM4E (0.41) ADORA3ADORA2AADORA1KDM4EL3MBTL1
SCHEMBL30976294 0.69 KAT2B (0.46) KDM4EL3MBTL1ALDH1A1TET2TET1
SCHEMBL15197861 0.68 SSTR4 (0.42) MYCKDM4EL3MBTL1ALDH1A1CYP3A4
SCHEMBL4550466 0.66 KDM4C (0.52) MYCKDM4EL3MBTL1ALDH1A1CYP3A4
SCHEMBL29615760 0.66 ADORA3 (0.49) ADORA3ADORA2AADORA1PARP1GRM4
SCHEMBL29824628 0.66 GABRA1 (0.40) ADORA3ADORA2AADORA1KDM4EL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250011327-A1 TRICYCLIC COMPOUNDS JACOBIO PHARMACEUTICALS CO LTD (CN) 2025-01-09 US disclosed
US-12103929-B2 Tricyclic compounds JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-10-01 US disclosed
US-11466005-B2 Tricyclic compounds JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2022-10-11 US disclosed
CN-115109061-A Tricyclic compounds 北京加科思新药研发有限公司 2022-09-27 CN disclosed
CN-112513041-B Tricyclic compounds 北京加科思新药研发有限公司 2022-05-10 CN disclosed
US-20220119390-A1 TRICYCLIC COMPOUNDS JACOBIO PHARMACEUTICALS CO LTD (CN) 2022-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011327-A1 TRICYCLIC COMPOUNDS BRD4, BET1, BRD3 ADORA3 4688/4885ADORA2A 4671/4885ADORA1 4649/4885
US-11466005-B2 Tricyclic compounds BRD4, BET1, BRD3 ADORA3 4688/4885ADORA2A 4671/4885ADORA1 4649/4885
US-12103929-B2 Tricyclic compounds BRD4, BET1, BRD3 ADORA3 4688/4885ADORA2A 4671/4885ADORA1 4649/4885
US-20220119390-A1 TRICYCLIC COMPOUNDS BRD4, BET1, BRD3 ADORA3 4688/4885ADORA2A 4671/4885ADORA1 4649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.